Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Scynexis, Inc.
Patients will receive initial intravenous (IV) echinocandin therapy. Patients who are eligible for randomization will receive SCY-078 500-mg orally, SCY-078 750-mg orally, or standard-of-care.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of invasive candidiasis defined as a positive culture of blood or from another normally sterile site for Candida.
Not of reproductive potential or if of reproductive potential, agrees to remain abstinent or use 2 methods of contraception.
You may not be if
Patient with Candida endocarditis, osteomyelitis, meningitis, or chronic disseminated candidiasis or evidence of endophthalmitis.
Patient has failed treatment with an echinocandin for this episode of invasive candidiasis.
Infection limited to the oropharynx, esophagus, urogenital system, or skin, or sputum/bronchoalveolar lavage culture.
Participation in a clinical study with other investigational drug(s) within 30 days prior to study entry or during this study.
Clareo Health | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
